‘What is dead may never die’ — Cost-minimization analysis in the context of medical devices in Europe by Raymakers, AJN et al.
‘What is dead may never die’ — Cost-minimization analysis in the context of medical 
devices in Europe  
A.J.N. Raymakers ∗ 
Health Economics and Policy Analysis Centre, National University of  Ireland Galway, Galway, Ireland  
CURAM Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland  
S. O’Neill  
Health Economics and Policy Analysis Centre, National University of  Ireland Galway, Galway, Ireland  
N. O’Leary  
Health Research Board (HRB), Clinical Research Facility, National University of Ireland Galway, Galway, Ireland  
P. Gillespie  
Health Economics and Policy Analysis Centre, National University of  Ireland Galway, Galway, Ireland  
CURAM Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland  
Introduction  
The application of health economic evaluation methods to inform reimbursement decisions 
for medical devices has been markedly different from pharmaceutical products. Methods such 
as cost-utility analysis (CUA) and cost-effectiveness analysis (CEA) have been widely applied 
to inform decision-making for the latter, but generally not for the former. The relative lack of 
application of the methods of economic evaluation for medical devices is related to several 
factors, including the nature of the development and usage of medical devices themselves, 
which often inhibits the generation of evidence for the evaluative process, and the regulatory 
environment, which dictates the level of evidence that is provided to inform approval and 
reimbursement decisions [1]. This issue has been discussed in detail in several previous 
publications [1–3]. However, recent changes to the regulatory environment will likely lead to 
increased requirements for economic evidence on medical devices, particularly, but not limited 
to high-risk or ‘Class III’ devices [4]. The nature of the regulatory changes, along with the 
complexity of applying economic evaluation methods to medical devices, will have important 
implications for practitioners and users of these methods going forward. In this article, we 
consider one such implication: the potential re-emergence of cost minimisation analysis (CMA) 
as a method of economic evaluation for medical devices resulting from new evidentiary 
requirements. In 2001, Briggs and O’Brien published an article in the journal Health Economics 
entitled the ‘The death of cost-minimization analysis?’ [5]. In their article, the authors argued 
that unless a study has been specifically designed to show the clinical equivalence of treatments 
in terms of effects, it is inappropriate to conduct CMA. Indeed, their article informed current 
‘best practices’ in economic evaluation whereby the majority of analyses currently take the 
form of CEA or CUA, rather than CMA. Given the regulatory changes outlined below, it is 
timely to consider whether the updated guidelines might lead to the re-emergence of CMA as a 
method to inform reimbursement decisions for medical devices and the inappropriate use of 
this method in this context if clinical equivalence is not considered.  
The regulatory environment for medical devices and the implications for health 
economic evaluation  
The regulatory framework for the approval of medical devices in the European Union (EU) 
has recently been revised and is  
currently in a transition phase prior to new regulations being fully implemented by 2020 [4]. 
As a component of the changes, all devices currently in use may face a need to be re-approved, 
without current devices necessarily being given any special status. While the details of this 
aspect of the change in policy are yet to be confirmed, what is clear is that the requirements for 
device approval will become more stringent. Two significant implications for medical device 
reimbursement decisions may result; first, currently used medical devices may need to be re-
approved and, as such, may require evidence for re-approval, presumably incorporating some 
form of economic evaluation. Second, the incoming process for device approval will likely 
require greater standards of clinical evidence than the previous process where approval of a 
device could be based entirely on technical and biological equivalence to predicate devices. 
The consequence of this change in policy will be an increased requirement on manufacturers to 
conduct clinical investigations for device approval, while at the same time reimbursement 
agencies are increasingly requiring economic evidence to inform decisions [6].  
The generation of clinical and economic evidence for the approval of health technologies 
involves the comparison of the new technology to the existing standard of care. Typically, to 
generate clinical evidence for the superiority of a new health intervention, a randomized 
controlled trial (RCT) is conducted to determine the efficacy of the intervention in comparison 
to another intervention or placebo; this data is often a primary data source for an economic 
evaluation. Economic evaluation typically involves conducting an incremental analysis, 
calculating point estimates for the incremental costs and effects of the alternatives, and 
quantifying the uncertainty around those point estimates [7]. If the new health intervention is 
more costly and more effective than the alternative, then an incremental cost-effectiveness 
ratio (ICER) is calculated and compared to a country- (or region-) specific cost-effectiveness 
threshold value [7]. Most reimbursement agencies prefer that economic evaluations take the 
form of a CUA, whereby health benefit is quantified using the quality-adjusted life-year 
(QALY), an outcome measure that simultaneously incorporates both quality and quantity of 
life, and is comparable across disease areas. For certain interventions, CEA may also be used, 
but this typically requires explicit justification, as benefits are measured in terms of natural 
units and are often limited to a specific disease. The central feature of both CUA and CEA is 
to estimate the joint distribution of costs and effects, and the uncertainty around those 
estimates, of an intervention relative to the standard of care. It is this feature that clearly 
distinguishes CEA and CUA from CMA as a means of economic evaluation.  
A key issue that arises in the case of medical devices, in contrast to pharmaceuticals, is that 
medical device development is often iterative in nature, with small changes to the structure and 
materials of a device leading to incremental changes in its safety profile, ease of use, and 
performance. In this context, the superiority RCT might not be the principal method used to 
generate evidence for new devices or new iterations of existing devices [8]. This evidence, 
instead, may come from trials that only aim to show non-inferiority or the clinical equivalence 
of a device relative to the standard of care [9]. It is in this specific context that the case may re-
emerge for CMA. In CMA, the effectiveness of the alternative strategies is deemed to be 
‘equivalent’, often without consideration of the uncertainty surrounding this equivalence, and 
the cost-effectiveness of an intervention is determined solely if the new alternative is cost-
saving. A key point raised by Briggs and O’Brien [5] , and further developed by Dakin and 
Wordsworth [10] , becomes relevant here; that is, unless a study is specifically designed to have 
a pre-specified acceptable equivalence or non-inferiority margin [11] and sufficient sample size 
to ensure adequate power to determine non-inferiority, then CMA is an inappropriate approach 
and may bias reimbursement decisions. We direct the interested reader to these publications for 
further details on the limitations of CMA, and how its use might lead to poor health services 
decisions [5,10].  
Under the updated EU regulations for medical devices, an important theme is the need for 
new devices to show, at minimum, ‘equivalence’ to the existing standard of care [4]. The 
regulations state, “A clinical evaluation may be based on clinical data relating to a device for 
which equivalence to the device in question can be demonstrated ” and that under this claim of 
equivalence the technical, biological, and clinical characteristics of the device shall “be similar 
to the extent that there would be no clinically significant difference in the safety and clinical 
performance of the device”. The guidelines further state that, “Considerations of equivalence 
shall be  
based on proper scientific justification.” 
 
If the standard for efficacy data for medical devices becomes that of clinical equivalence, then 
CMA could conceivably re-emerge as a method of economic evaluation. Certainly, given the 
nuances that exist for evidence generation in the context of medical devices [1] , it seems 
logical that the requirement for clinical evidence for approval and reimbursement might shift 
away from the superiority RCT design, and toward ‘non-inferiority’ or ‘equivalence’ RCTs. 
Should this happen, it will pose important challenges for reimbursement agencies charged 
with generating and interpreting economic evidence for decisions regarding medical devices. 
If the nature of the data provided for a medical device is of insufficient quality to demonstrate 
clinical equivalence, but is viewed as ‘equivalent’ in terms of some other technical, biological, 
or clinical characteristics, then the application of CMA will be inappropriate and can lead to 
suboptimal reimbursement decisions.  
This leaves reimbursement agencies with two practical problems. First, the guidelines for 
economic evaluation in most jurisdictions recommend the use of CUA (or CEA), which is often 
reliant on data from superiority RCTs. In the case of medical devices, however, this approach 
to economic evaluation might not be directly applicable, and may need to be adapted. Second, 
if CMA does re-emerge, agencies should be critical of this approach and ensure that the 
evidence underpinning such analyses adequately addresses the question of clinical equivalence, 
in terms of acceptable, pre-specified non-inferiority or equivalence margins and sufficient 
sample sizes to power the study. What is clear is that reimbursement agencies should consider 
carefully the consequences stemming from the new regulations in terms of the re-emergence of 
CMA and its usage leading to potentially incorrect decision-making.  
Concluding comment  
We suspect that an unintended consequence of the new regulatory environment for medical 
devices in Europe may be the re-emergence of CMA to provide economic evidence for 
reimbursement decisions. While this may appear to be an attractive option for medical devices 
manufacturers given new evidentiary requirements, we assert that decision-makers should 
carefully consider the limitations of this method. However, we simultaneously acknowledge 
the pragmatic reality of evidence generation in the case of medical device technologies and 
the pressures this reality places on manufacturers and reimbursement agencies. We therefore 
argue that a discussion needs to begin involving EU regulatory and reimbursement agencies, 
medical device manufacturers, patient groups, and analysts conducting economic evaluations 
on the nature of economic evidence generation in the context of medical devices. Indeed, with 
this article, we hope to provide an impetus for such a discussion to ensure agencies charged 
with making reimbursement decisions have the best possible evidence, and not simply the 
most convenient, with which to make those decisions.  
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